The problem was never just the ovary, and never just about fertility.
Durante décadas, millones de mujeres cargaron con un diagnóstico cuyo nombre las alejaba de la verdad sobre su propia salud. Este año, un consenso científico internacional publicado en The Lancet renombró oficialmente el Síndrome de Ovario Poliquístico como Síndrome Metabólico Poliendocrino de Ovario, reconociendo que la condición nunca fue exclusivamente ovárica, sino una alteración profunda del sistema hormonal y metabólico. El cambio no es solo semántico: es una corrección de una imprecisión que costó años de diagnósticos tardíos y síntomas normalizados a una de cada ocho mujeres en el mundo.
- El nombre antiguo no era solo inexacto —era una trampa conceptual que orientaba tanto a médicos como a pacientes hacia los ovarios, ignorando un desorden metabólico y endocrino de alcance sistémico.
- Millones de mujeres vivieron años sin diagnóstico claro porque sus síntomas —resistencia a la insulina, acné persistente, caída del cabello, irregularidades menstruales— no encajaban en el marco reproductivo que el viejo nombre imponía.
- El proceso de renombramiento involucró a 56 organizaciones internacionales y más de 14.000 pacientes y profesionales de salud, lo que le otorga al cambio un peso científico y humano difícil de ignorar.
- La detección temprana es ahora el eje central del nuevo enfoque: identificar el SOMP en la adolescencia puede prevenir complicaciones metabólicas y hormonales que de otro modo se acumulan silenciosamente durante años.
- Un plan de implementación de tres años busca integrar la nueva terminología en universidades, sistemas de salud y guías clínicas globales, reconociendo que cambiar un nombre también exige cambiar una forma de pensar.
Durante décadas, millones de mujeres vivieron con una condición cuyo nombre las engañaba sobre lo que realmente ocurría en sus cuerpos. El Síndrome de Ovario Poliquístico evocaba imágenes de quistes ováricos, un problema reproductivo, una cuestión de fertilidad. Pero la enfermedad nunca fue tan simple, y el nombre, según los expertos, era fundamentalmente erróneo.
Este año, un consenso científico internacional publicado en The Lancet lo renombró oficialmente como Síndrome Metabólico Poliendocrino de Ovario, o SOMP. El cambio refleja lo que los investigadores han comprendido desde hace tiempo: que no se trata principalmente de un trastorno ovárico, sino de una alteración compleja de los sistemas hormonal y metabólico que puede afectar casi todos los aspectos de la salud de una mujer. Sergio Wehinger, académico de la Universidad de Talca, explicó que lo que aparece en el ultrasonido como 'quistes' son en realidad pequeños folículos en una etapa intermedia de maduración, y que el problema real se extiende mucho más allá de los ovarios y de la fertilidad.
El error de nomenclatura tuvo consecuencias reales. Una de cada ocho mujeres padece este síndrome, pero muchas vivieron años sin comprender lo que les ocurría, con síntomas normalizados o atribuidos a otras causas. Las señales de alerta —acné persistente, caída del cabello, ciclos menstruales irregulares o dolorosos, acumulación de grasa abdominal— pueden aparecer desde la adolescencia, pero el enfoque reproductivo del viejo nombre hacía que frecuentemente pasaran inadvertidas.
Wehinger subrayó que la detección temprana es crucial para prevenir complicaciones metabólicas y hormonales que se acumulan silenciosamente con los años. El renombramiento no fue una decisión casual: surgió de un proceso riguroso que involucró a 56 organizaciones internacionales y más de 14.000 pacientes y profesionales de salud. La comunidad médica se comprometió con un plan de implementación de tres años para integrar la nueva terminología en universidades, sistemas de salud y guías clínicas. Para las mujeres que pasaron años confundidas por un diagnóstico que nunca encajó del todo con su experiencia, el cambio representa algo más profundo: la posibilidad de ser vistas, por fin, con claridad.
For decades, millions of women have lived with a condition whose very name misled them about what was actually happening inside their bodies. Polycystic Ovary Syndrome—the term itself conjured images of cysts clustered on the ovaries, a reproductive problem, a fertility issue. But the disease was never that simple, and the name, according to medical experts, was fundamentally wrong.
This spring, an international scientific consensus published in The Lancet officially renamed the condition Metabolic Polyendocrine Ovary Syndrome, or SOMP. The change reflects what researchers have long understood: that this is not primarily an ovarian disorder at all, but a complex disruption of hormonal and metabolic systems that can ripple through nearly every aspect of a woman's health. Sergio Wehinger, a faculty member in the School of Health Sciences at the University of Talca, explained that the old terminology was not merely imprecise—it was actively misleading. What appears on ultrasound as "cysts" are actually small follicles caught in an intermediate stage of maturation. The real problem, he emphasized, extends far beyond the ovaries and far beyond fertility. It is an endocrine and metabolic disorder of much broader consequence.
The naming error had real consequences. Because the condition was framed as an ovarian or reproductive issue, diagnoses were delayed. Women whose symptoms fell outside the narrow reproductive frame—metabolic irregularities, hormonal imbalances, systemic complications—went unrecognized or were dismissed as separate problems entirely. One in eight women experience this syndrome, yet many lived for years without understanding what was happening to their bodies, their symptoms normalized or minimized by a medical vocabulary that simply did not account for what they were experiencing.
The warning signs are often visible early. Persistent acne, hair loss, irregular or painful menstrual cycles, accumulation of fat around the abdomen—these can all be signals of SOMP, sometimes appearing as early as adolescence. Elevated levels of Anti-Müllerian Hormone in the blood are associated with the condition. Family history, insulin resistance, and difficulty regulating blood sugar are additional markers. Yet because the old name anchored the disease to the ovaries, these systemic symptoms were frequently overlooked or attributed to other causes.
Wehinger stressed that early detection is crucial. Identifying the condition sooner can prevent long-term metabolic and hormonal complications that accumulate silently over years. The new name, he argued, creates space for a more complete understanding—one that allows women to recognize their own symptoms and allows clinicians to see the full picture of what is happening.
The renaming was not a casual decision. It emerged from a rigorous process involving 56 international organizations and input from more than 14,000 patients and healthcare professionals. The medical community has committed to a three-year implementation timeline, during which universities, healthcare systems, and clinical guidelines will gradually adopt the new terminology. This deliberate pace acknowledges the scale of the shift required—not just a name change, but a fundamental reorientation of how the condition is understood, taught, and treated. For women who have spent years confused by a diagnosis that never quite fit their experience, the change represents something larger: the possibility of finally being seen clearly.
Citações Notáveis
The old term was inexact and even erroneous—this is not a syndrome in which the ovary has multiple cysts, but rather a broader endocrine and metabolic disorder.— Sergio Wehinger, University of Talca
Early detection of symptoms like acne, hair loss, irregular periods, and abdominal weight gain can prevent long-term metabolic and hormonal complications.— Sergio Wehinger, University of Talca
A Conversa do Hearth Outra perspectiva sobre a história
Why did the old name persist for so long if doctors knew it was inaccurate?
Because naming is powerful and sticky. Once a term enters medical education and clinical practice, it becomes the lens through which everyone sees the disease. Changing it requires consensus across institutions, and that takes time. But more importantly, the old name reflected what was visible on ultrasound—the follicles that looked like cysts—so it felt descriptive enough, even if it was incomplete.
What does the new name actually tell us that the old one didn't?
It tells us this is not a reproductive problem that happens to affect hormones. It's a metabolic and endocrine problem that happens to affect the ovaries. That shift in emphasis changes everything about how you diagnose it, treat it, and understand what symptoms belong to it.
You mentioned symptoms being normalized. What does that mean in practice?
A teenager with irregular periods and acne might be told that's just puberty. A woman with weight gain around her abdomen might be told to diet. These are real symptoms of SOMP, but because the condition was framed as ovarian, nobody connected the dots. Women lived with fragmented diagnoses instead of understanding they had one systemic condition.
Why does early detection matter so much?
Because metabolic damage compounds. Insulin resistance, if unaddressed, leads to diabetes. Hormonal imbalances affect bone density, cardiovascular health, mental health. Catch it early, and you can intervene before those cascading problems take hold.
Three years to implement this globally seems like a long time.
It is, but it's also realistic. You have to retrain doctors, rewrite textbooks, update hospital protocols, change how medical students learn. You can't do that overnight. The timeline acknowledges that this is a genuine shift in medical understanding, not just a cosmetic fix.